US 11,865,150 B2
Materials and methods for treating cancer
Evanthia Galanis, Rochester, MN (US); S. Keith Anderson, Rochester, MN (US); Cheyne B. Kurokawa, Rochester, MN (US); and Ianko D. Iankov, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 16/477,830
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Jan. 11, 2018, PCT No. PCT/US2018/013324
§ 371(c)(1), (2) Date Jul. 12, 2019,
PCT Pub. No. WO2018/132571, PCT Pub. Date Jul. 19, 2018.
Claims priority of provisional application 62/532,709, filed on Jul. 14, 2017.
Claims priority of provisional application 62/446,131, filed on Jan. 13, 2017.
Prior Publication US 2019/0365836 A1, Dec. 5, 2019
Int. Cl. A61K 39/12 (2006.01); A61K 35/768 (2015.01); A61K 31/519 (2006.01); C12N 15/86 (2006.01); G01N 33/574 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 31/519 (2013.01); C12N 15/86 (2013.01); G01N 33/57484 (2013.01); C12N 2760/18432 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for treating cancer in a mammal, wherein said method comprises:
(a) identifying said mammal as having cancer cells that have a virotherapy permissive interferon (IFN)-stimulated gene (ISG) signature, wherein said virotherapy permissive ISG signature comprises a decreased level of expression of at least 6 ISGs selected from the group consisting of HLA-A, HLA-B, HLA-C, HLA-E, HLA-G, IFI27, IFI35, IFI6, IFIT1, IFIT3, IRF1, IRF2, IRF9, ISG15, MX1, MX2, OAS1, OAS2, OAS3, OASL, SOCS1, and STAT2, wherein said virotherapy permissive ISG signature indicates that said cancer cells are responsive to treatment with an oncolytic virus; and
(b) administering said oncolytic virus to said mammal under conditions wherein the number of cancer cells within said mammal is reduced.